Opto Circuits India Limited (OCI), India’s leading manufacturer of medical diagnostics and interventional products, California-based international marketing arm, Mediaid Inc., announced the receipt of Brazilian FDA agency - Agencia Nacional de Vigilancia Sanitaria (ANVISA) - approval for marketing and sale of the Mediaid brand of US FDA-approved Pulse Oximetry (SPO2) products (Patient Monitors & Sensors) in the country and surrounding geographies.
Jayesh Patel, Director, OCI, commented, “Brazil is the largest medical device market in Latin America and an access into the country’s healthcare industry will help enhance peripheral geography sales too. Growth in Brazil’s private health insurance and a hospital modernization drive by the government along with a strong consumer demand for latest technologies will drive further growth. Our SPO2 products are amongst the best in the world and we are confident of using the present opportunities to grow our market share in the geography.”
Pulse oximetry (detection of arterial oxygen saturation and heart beat rate) is one of the five ‘vital signs’ that are monitored on a patient. Continuous oxygenation monitoring in hospitals and other critical care settings is now a standard of care.
Mediaid products that will be sold in Brazil are: Model M30, M34, M900, M960 and variants thereof.
About Opto Circuits (India) Ltd.
Opto Circuits (India) Ltd. (OCI) (BSE Code: 532391; NSE Symbol: OPTOCIRCUI) is a 100 percent EOU and a leading manufacturer of healthcare equipments in India. The product profile includes digital thermometers, sensors, probes, pulse oximeters, patient monitoring systems, stents, catheters and other innovative products. In 2001, OCI acquired 60 per cent stake in Advanced Micronic Devices (AMDL) to market and distribute its products in India. Mediaid came into existence with the acquisition of the patient monitoring division of Palco Labs, US, in end-2003 and it now directly markets OCI’s products in the US. OCI acquired EuroCor GmbH in 2006. EuroCor manufactures Cardiac Stents of various types, including Drug Eluting Coronary stents used in critical cardiac care. In April 2007, OCI ventured into new product segments - Urology, Gastroenterology, Gynecology and Orthopedics after acquiring Devon Innovations Private Limited (Bangalore) and Ormed Medical Technology Limited (Chennai). OCI completed the acquisition of US based Criticare Systems, Inc. in April 2008. Criticare designs, manufactures, and markets leading edge patient monitoring systems, vital signs monitors and gas benches for a wide range of hospitals and alternate health care environments throughout the world. Visit us at www.optoindia.com.
